RxDoctor Payments Data

Neil Stein, MD

Cardiology · Great Neck, NYNPI 1982631966

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 49.9% of the total. 2025 is the largest year on record at $189, 7.0 times the $27 reported in 2022. That places this record below the midpoint for cardiology clinicians in NY, where the typical reported total is $252.

$238in general payments, 2019–2025

Across 8 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$119
  • Pfizer$70
  • E.r. Squibb & Sons, L.L.C.$27
  • Abbott$23

What the payments were for

  • Food & beverage$238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$238 in reported general payments places this provider in the 45th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$356,112
Medicare patients
699
Services billed
4,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$268,264
JardianceEmpagliflozin207$221,308
XareltoRivaroxaban155$193,572
CamzyosMavacamten18$151,925
EntrestoSacubitril/Valsartan95$93,750
Repatha SureclickEvolocumab44$40,686
OzempicSemaglutide17$24,502
FarxigaDapagliflozin Propanediol14$22,963
Praluent PenAlirocumab24$16,021
WegovySemaglutide12$15,818
Candesartan Cilexetil65$5,225
Ezetimibe161$4,914
Metoprolol Succinate309$4,786
Bisoprolol Fumarate151$4,353
Rosuvastatin Calcium251$4,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$268,264257 claims
E.r. Squibb & Sons, L.L.C.Camzyos$27$151,92518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 112 cardiology providers in New York.

Other cardiology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →